The study found that treatment with biological DMARDs (bDMARDs), specifically TNF inhibitors like etanercept, adalimumab, and infliximab, was associated with a reduced risk of dementia in patients with rheumatoid arthritis (RA). Conventional synthetic DMARDs (csDMARDs) did not show the same protective effects. The meta-analysis included 12 datasets with over 940,000 patients and found a significant reduction in dementia risk with bDMARD treatment compared to csDMARDs. Subgroup analyses also showed TNF inhibitors had the most significant impact on reducing dementia risk. However, study limitations included biases and restricted generalizability, highlighting the need for controlled clinical trials on TNF inhibitors’ neuroprotective potential.
Source link
Biological DMARDs May Lower Dementia Risk in Rheumatoid Arthritis
